ProCE Banner Activity

Addressing Gaps in SGLT2 Inhibitor Use in Heart Failure Management

Clinical Thought

In this commentary, an expert discusses critical gaps in heart failure management, including barriers to using the highly beneficial SGLT2 inhibitors. Learn how to overcome such barriers to optimize patient outcomes.

Released: February 12, 2025

Expiration: February 11, 2026

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Boehringer Ingelheim Pharmaceuticals, Inc.

Eli Lilly and Company

Disclosure

Primary Author

Ty J. Gluckman, MD, MHA

Medical Director
Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

Ty J. Gluckman, MD, MHA, has no relevant financial relationships to disclose.